Citations (22)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Peter Novodvorský & Martin Haluzík. (2022) An update on the safety of insulin-GLP-1 receptor agonist combinations in type 2 diabetes mellitus. Expert Opinion on Drug Safety 21:3, pages 349-361.
Read now
Read now
Johannes Pöhlmann, Roberta Montagnoli, Giusi Lastoria, Witesh Parekh, Marie Markert & Barnaby Hunt. (2019) Value For Money In The Treatment Of Patients With Type 2 Diabetes Mellitus: Assessing The Long-Term Cost-Effectiveness Of IDegLira Versus iGlarLixi In Italy. ClinicoEconomics and Outcomes Research 11, pages 605-614.
Read now
Read now
Articles from other publishers (20)
Rui Wang, Shuoming Luo, Zilin Xiao & Zhiguang Zhou. (2023) Efficacy and safety of fixed‐ratio combination insulin degludec/liraglutide in type 2 diabetes: A systematic review and meta‐analysis of randomised controlled trials. Diabetes/Metabolism Research and Reviews.
Crossref
Crossref
Juan Carlos Garnica-Cuellar, Enrique Morales-Villegas, Carmen Alicia López-Forero, Bárbara Monroy-Cruz, Bhrugu Pariti, Swati Deshwal, Manisha Sekharan, Mariana Osorio-Hernández & Ida Caterina García-Appendini. (2023) A Relative Cost of Control Analysis of IDegLira versus Other Forms of Basal Insulin Intensification in Mexico. PharmacoEconomics - Open.
Crossref
Crossref
Hernando Vargas-Uricoechea, Juan Pablo Frias & Hernando David Vargas-Sierra. (2023) Fixed-ratio Combinations (basal Insulin Plus GLP-1RA) In Type 2 Diabetes. an Analytical Review Of Pivotal Clinical Trials. Review of Diabetic Studies 19:1, pages 14-27.
Crossref
Crossref
Ivona Risovic, Mirjana Sumarac Dumanovic, Mirjana Bojic & Danijel Djekic. (2023) Direct comparison two fixed-ratio combination glucagon-like peptide receptor agonist and basal insulin on glycemic and non glycemic parameters in type 2 diabetes. BMC Endocrine Disorders 23:1.
Crossref
Crossref
Andrej Janez, Emir Muzurovic, Anca Pantea Stoian, Martin Haluzik, Cristian Guja, Leszek Czupryniak, Lea Duvnjak, Nebojsa Lalic, Tsvetalina Tankova, Pawel Bogdanski, Nikolaos Papanas, Josè Silva Nunes, Peter Kempler, Zlatko Fras & Manfredi Rizzo. (2022) Translating results from the cardiovascular outcomes trials with glucagon-like peptide-1 receptor agonists into clinical practice: Recommendations from a Eastern and Southern Europe diabetes expert group. International Journal of Cardiology 365, pages 8-18.
Crossref
Crossref
Sándor Szépkúti, Szilvia Bandur, Gábor Kovács, Tamás Ferenci, Márk M. Svébis, Piroska Turbucz & Ádám G. Tabák. (2022) Real-world effectiveness of IDegLira compared with intensified conventional insulin therapy in adults with type 2 diabetes: a retrospective cohort study. BMC Endocrine Disorders 22:1.
Crossref
Crossref
Karan Vadher, Hiren Patel, Reema Mody, Joshua A. Levine, Meredith Hoog, Alice YY. Cheng, Kevin M. Pantalone & Hélène Sapin. (2022) Efficacy of tirzepatide 5, 10 and 15 mg versus semaglutide 2 mg in patients with type 2 diabetes: An adjusted indirect treatment comparison. Diabetes, Obesity and Metabolism 24:9, pages 1861-1868.
Crossref
Crossref
Gábor Winkler. (2022) GLP1-receptor-agonisták a 2-es típusú diabetes vércukorcsökkentő kezelésében. Orvosi Hetilap 163:29, pages 1144-1151.
Crossref
Crossref
Rory J. McCrimmon, Edel Falla, Jo Zhou Sha, Abdul Jabbar Omar Alsaleh, Elisheva Lew, Richard Hudson, Mike Baxter & Karen Palmer. (2021) Cost-Effectiveness of iGlarLixi in People with Type 2 Diabetes Mellitus Suboptimally Controlled on Basal Insulin Plus Metformin in the UK. Diabetes Therapy 12:12, pages 3217-3230.
Crossref
Crossref
Richard E. Pratley, Andrei‐Mircea Catarig, Ildiko Lingvay, Adie Viljoen, Abby Paine, Jack Lawson, Barrie Chubb, Anders Gorst‐Rasmussen & Nino Miresashvili. (2021) An indirect treatment comparison of the efficacy of semaglutide 1.0 mg versus dulaglutide 3.0 and 4.5 mg. Diabetes, Obesity and Metabolism 23:11, pages 2513-2520.
Crossref
Crossref
Fernando Gomez‐Peralta, Ebaa Al‐Ozairi, Edward B. Jude, Xiaoying Li & Julio Rosenstock. (2021) Titratable fixed‐ratio combination of basal insulin plus a glucagon‐like peptide‐1 receptor agonist: A novel, simplified alternative to premix insulin for type 2 diabetes. Diabetes, Obesity and Metabolism 23:7, pages 1445-1452.
Crossref
Crossref
Giuseppe Lisco, Anna De Tullio, Edoardo Guastamacchia & Vincenzo Triggiani. (2021) Fixed-Ratio Combinations of Basal Insulin and GLP-1RA in the Management of Type 2 Diabetes Mellitus: Highlights from the Literature. Endocrine, Metabolic & Immune Disorders - Drug Targets 21:4, pages 626-646.
Crossref
Crossref
Francesco Giorgino, Irene Caruso & Raffaele Napoli. (2020) Titratable fixed-ratio combination of insulin glargine plus lixisenatide: A simplified approach to glycemic control in type 2 diabetes mellitus. Diabetes Research and Clinical Practice 170, pages 108478.
Crossref
Crossref
Philip D. Home, Vanita R. Aroda, Lawrence Blonde, Patricia Guyot, Alka Shaunik, Mir Sohail Fazeli, Hardik Goswami, Sanjay Kalra & Mir‐Masoud Pourrahmat. (2020)
Efficacy and safety of
iGlarLixi
versus
IDegLira
in adults with type 2 diabetes inadequately controlled by glucagon‐like peptide‐1 receptor agonists: a systematic literature review and indirect treatment comparison
. Diabetes, Obesity and Metabolism 22:11, pages 2170-2178.
Crossref
Crossref
Young-A Heo. (2020) Insulin degludec/liraglutide in type 2 diabetes: a profile of its use. Drugs & Therapy Perspectives 36:6, pages 219-229.
Crossref
Crossref
Ping Wu, Zhenyu Liu, Xiaohong Jiang & Hao Fang. (2020) An Overview of Prospective Drugs for Type 1 and Type 2 Diabetes. Current Drug Targets 21:5, pages 445-457.
Crossref
Crossref
Emma Deeks. (2019) Insulin glargine/lixisenatide in type 2 diabetes: a profile of its use. Drugs & Therapy Perspectives 35:10, pages 470-480.
Crossref
Crossref
Maria Ida Maiorino, Paolo Chiodini, Giuseppe Bellastella, Lorenzo Scappaticcio, Miriam Longo, Dario Giugliano & Katherine Esposito. (2019) The good companions: insulin and glucagon-like peptide-1 receptor agonist in type 2 diabetes. A systematic review and meta-analysis of randomized controlled trials. Diabetes Research and Clinical Practice 154, pages 101-115.
Crossref
Crossref
Johannes Pöhlmann, Monika Russel-Szymczyk, Pavel Holík, Karel Rychna & Barnaby Hunt. (2019) Treating Patients with Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin in the Czech Republic: Cost-Effectiveness of IDegLira Versus iGlarLixi. Diabetes Therapy 10:2, pages 493-508.
Crossref
Crossref
Leigh Perreault, Helena Rodbard, Virginia Valentine & Eric Johnson. (2019) Optimizing Fixed-Ratio Combination Therapy in Type 2 Diabetes. Advances in Therapy 36:2, pages 265-277.
Crossref
Crossref